In the News

FDA’s Shift From Animal Testing Opens Doors for Organoid Makers

The idea that a mouse brain or a rat brain or any other animal brain can predict how a human brain would react to a particular drug—it's not credible. Yet up until this point, this has been the only solution that pharma has had available to them.

April 30, 2025

-

‍

Spotlight

2/5/2026

Organoid Intelligence Offers New Evidence of Learning-related Activity in Human Neural Tissue

Human-derived neural networks can exhibit measurable markers of learning and memory processes.

In the News

7/17/2023

AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX Assets

AxoSim has entered a definitive agreement to acquire Vyant Bio's StemoniX microBrain™ platform, uniting top-tier organoid technologies to accelerate neurological drug discovery.

In the News

2/28/2024

AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors

Serial Entrepreneurs Dale Pfost and David Weiner Bring Broad Expertise as AxoSim Expands Its Leadership in Human Organoid Technologies Designed to Make Neurological R&D Faster, More Efficient and More Successful.

FDA’s Shift From Animal Testing Opens Doors for Organoid Makers

The idea that a mouse brain or a rat brain or any other animal brain can predict how a human brain would react to a particular drug—it's not credible. Yet up until this point, this has been the only solution that pharma has had available to them.

Related Stories